Literature DB >> 24535462

Parkinson disease: Intestinal levodopa infusion in PD--the first randomized trial.

Regina Katzenschlager1, Werner Poewe2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24535462     DOI： 10.1038/nrneurol.2014.26

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  10 in total

Review 1.  The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease.

Authors:  Susan H Fox; Regina Katzenschlager; Shen-Yang Lim; Bernard Ravina; Klaus Seppi; Miguel Coelho; Werner Poewe; Olivier Rascol; Christopher G Goetz; Cristina Sampaio
Journal:  Mov Disord       Date:  2011-10       Impact factor: 10.338

2.  Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease.

Authors:  Cory Toth; Kim Breithaupt; Shaohua Ge; Yanjun Duan; Joan M Terris; Anita Thiessen; Samuel Wiebe; Douglas W Zochodne; Oksana Suchowersky
Journal:  Ann Neurol       Date:  2010-07       Impact factor: 10.422

Review 3.  Subthalamic neurostimulation for Parkinson's disease with early fluctuations: balancing the risks and benefits.

Authors:  Günther Deuschl; Yves Agid
Journal:  Lancet Neurol       Date:  2013-10       Impact factor: 44.182

Review 4.  Pharmacokinetics and pharmacodynamics of levodopa.

Authors:  John G Nutt
Journal:  Mov Disord       Date:  2008       Impact factor: 10.338

5.  Complications and mortality after percutaneous endoscopic gastrostomy in geriatrics: a prospective multicenter observational trial.

Authors:  Rainer Wirth; Christian Voss; Christine Smoliner; Cornel C Sieber; Juergen M Bauer; Dorothee Volkert
Journal:  J Am Med Dir Assoc       Date:  2011-08-26       Impact factor: 4.669

Review 6.  Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications.

Authors:  C Warren Olanow; Jose A Obeso; Fabrizio Stocchi
Journal:  Lancet Neurol       Date:  2006-08       Impact factor: 44.182

7.  Risk factors and complications following percutaneous endoscopic gastrostomy: a case series of 1041 patients.

Authors:  Hans Juergen Richter-Schrag; Sabine Richter; Olaf Ruthmann; Manfred Olschewski; Ulrich Theodor Hopt; Andreas Fischer
Journal:  Can J Gastroenterol       Date:  2011-04       Impact factor: 3.522

Review 8.  Peripheral neuropathy in Parkinson's disease: levodopa exposure and implications for duodenal delivery.

Authors:  Thomas Müller; Teus van Laar; David R Cornblath; Per Odin; Fabian Klostermann; Francisco J Grandas; Georg Ebersbach; Peter P Urban; Francesc Valldeoriola; Angelo Antonini
Journal:  Parkinsonism Relat Disord       Date:  2013-02-27       Impact factor: 4.891

9.  Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study.

Authors:  C Warren Olanow; Karl Kieburtz; Per Odin; Alberto J Espay; David G Standaert; Hubert H Fernandez; Arvydas Vanagunas; Ahmed A Othman; Katherine L Widnell; Weining Z Robieson; Yili Pritchett; Krai Chatamra; Janet Benesh; Robert A Lenz; Angelo Antonini
Journal:  Lancet Neurol       Date:  2013-12-20       Impact factor: 44.182

10.  Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results.

Authors:  Hubert H Fernandez; Arvydas Vanagunas; Per Odin; Alberto J Espay; Robert A Hauser; David G Standaert; Krai Chatamra; Janet Benesh; Yili Pritchett; Steven L Hass; Robert A Lenz
Journal:  Parkinsonism Relat Disord       Date:  2013-01-01       Impact factor: 4.891
  10 in total
  2 in total

1.  Parkinson's disease: recent advances.

Authors:  Regina Katzenschlager
Journal:  J Neurol       Date:  2014-04-01       Impact factor: 4.849

2.  Simultaneous electrochemical detection of levodapa, paracetamol and l-tyrosine based on multi-walled carbon nanotubes.

Authors:  Zai-Yu Li; Dan-Yang Gao; Zhi-Yong Wu; Shuang Zhao
Journal:  RSC Adv       Date:  2020-04-07       Impact factor: 3.361
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.